Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aardvark Therapeutics, Inc. - Common Stock
(NQ:
AARD
)
3.750
-0.190 (-4.82%)
Streaming Delayed Price
Updated: 2:20 PM EDT, Jun 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
61,192
Open
3.910
Bid (Size)
3.750 (600)
Ask (Size)
3.780 (400)
Prev. Close
3.940
Today's Range
3.725 - 3.980
52wk Range
3.350 - 17.94
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
June 02, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
May 26, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Performance
YTD
-71.6%
-71.6%
1 Month
-31.4%
-31.4%
3 Month
-34.7%
-34.7%
6 Month
-69.8%
-69.8%
1 Year
-67.9%
-67.9%
More News
Read More
Here are the top movers in Friday's session.
↗
May 15, 2026
Via
Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
May 15, 2026
Via
Chartmill
These stocks are moving in today's pre-market session
↗
May 15, 2026
Via
Chartmill
Wondering what's happening in today's after-hours session?
↗
May 14, 2026
Via
Chartmill
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
May 14, 2026
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 07, 2026
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
March 24, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 23, 2026
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
March 17, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
March 10, 2026
From
Pomerantz LLP
Via
GlobeNewswire
AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
March 04, 2026
From
Schall Law
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
March 03, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Monday's session: top gainers and losers
↗
March 02, 2026
Via
Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
March 02, 2026
Via
Chartmill
AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial
↗
March 02, 2026
Via
Stocktwits
Get insights into the top gainers and losers of Monday's pre-market session.
↗
March 02, 2026
Via
Chartmill
AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation With the Schall Law Firm
February 28, 2026
From
The Schall Law Firm
Via
Business Wire
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts
↗
February 27, 2026
Via
Stocktwits
Top movers in Friday's after hours session
↗
February 27, 2026
Via
Chartmill
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome
February 27, 2026
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2026
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
Aardvark Therapeutics Announces Leadership Appointments
February 12, 2026
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer
February 12, 2026
From
Aardvark Therapeutics, Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is Aardvark Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aardvark Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aardvark Therapeutics, Inc. - Common Stock trade on?
Aardvark Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aardvark Therapeutics, Inc. - Common Stock?
The ticker symbol for Aardvark Therapeutics, Inc. - Common Stock is AARD on the Nasdaq Stock Market
What is the current price of Aardvark Therapeutics, Inc. - Common Stock?
The current price of Aardvark Therapeutics, Inc. - Common Stock is 3.750
When was Aardvark Therapeutics, Inc. - Common Stock last traded?
The last trade of Aardvark Therapeutics, Inc. - Common Stock was at 06/05/26 02:20 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
